Evidence analysisOctober 16, 2026Health & Science

Human medicines European public assessment report (EPAR): Kizfizo, temozolomide, Status: Opinion

FreedomWitness Evidence Engine: This is an AI-assisted original analysis built from the linked source and available public source context. It separates evidence from interpretation and may challenge conventional framing only where the evidence supports it. It is not a copied article.

Kizfizo (Temozolomide): New European Medicines Agency Opinion on Treatment for Glioma

This dossier examines the recent positive opinion issued by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) regarding Kizfizo, a new formulation of the chemotherapy drug temozolomide. The medicine is intended primarily for treating glioblastoma multiforme and other malignant gliomas in adults and children.

What Is Established

  • Kizfizo is a new oral suspension formulation of temozolomide, at 40 mg/ml concentration, developed by Orphelia Pharma.
  • Temozolomide is an alkylating antineoplastic agent that converts rapidly in the body to an active form causing DNA damage in tumor cells, leading to their death.
  • Kizfizo’s clinical indications include treatment of newly diagnosed glioblastoma multiforme in adults (combined with radiotherapy and then as monotherapy) and treatment of recurrent or progressive malignant gliomas in adults and children aged 1 year and above.
  • The CHMP’s opinion was adopted on 15 October 2026, recommending marketing authorization within the European Union.
  • Kizfizo is considered a hybrid medicine of the older drug Temodal, approved in the EU since 1999, with evidence showing bioequivalence and satisfactory manufacturing quality.
  • Kizfizo was granted orphan designation, recognizing it targets a rare and serious condition with limited existing treatment options.
  • The most common side effects reported include gastrointestinal symptoms (nausea, vomiting, constipation, diarrhoea), neurological effects (headache, convulsions, hemiparesis, speech disturbances), fatigue, hair loss, and rash.

What the Source Claims

The source, the European Medicines Agency (EMA), reports that combining Kizfizo with radiotherapy improves overall survival in adults with newly diagnosed glioblastoma multiforme compared with radiotherapy alone. For pediatric and adult patients with recurrent or progressive malignant glioma, Kizfizo showed increased progression-free survival compared to procarbazine, an alternative chemotherapy agent.

Kizfizo offers a new formulation as an oral suspension, which potentially facilitates dosing in younger pediatric patients (starting at 1 year), a group not extensively covered by older temozolomide formulations.

EMA emphasises that Kizfizo should be prescribed by physicians experienced in treating brain tumors and that detailed usage recommendations will be published in the official Summary of Product Characteristics (SmPC) upon marketing authorization.

What May Be Missing from the Usual Framing

  • The EMA communication focuses primarily on clinical efficacy outcomes (overall survival and progression-free survival) and known safety profiles but provides limited extensive data on long-term safety or comparison with other newer therapies available for glioma.
  • The overall survival benefits and improvements in pediatric populations may not be quantified in detail in this summary material, limiting assessment of the magnitude and clinical relevance of these improvements.
  • There is no detailed discussion on quality of life, cognitive function, or neurodevelopmental impacts in pediatric patients receiving Kizfizo, which would be relevant given the treatment’s use in very young children.
  • Economic or cost-effectiveness considerations, which often influence access and healthcare policy decisions for orphan and oncology drugs, are not discussed.
  • The input of patient advocacy groups or real-world patient experiences with temozolomide-based therapies are not addressed.

Competing Evidence or Uncertainty

The EMA opinion states the benefits of Kizfizo based on clinical trial comparisons, but independent confirmation or long-term observational studies to validate and compare these efficacy outcomes in routine clinical practice may be limited or not yet available.

Temozolomide has been the standard treatment for glioblastoma for over two decades, but glioblastoma remains a highly aggressive and usually fatal cancer. The degree of improvement in survival with temozolomide-based regimens is generally considered modest. Whether Kizfizo’s new formulation will substantially change clinical outcomes compared to older formulations is uncertain beyond the reported bioequivalence and dosing flexibility.

Other emerging treatments for glioma, including targeted therapies, immunotherapies, and experimental approaches, may compete or complement temozolomide use, but comparative evidence from head-to-head studies is scarce.

Why It Matters

Glioblastoma multiforme and other malignant gliomas are among the most difficult cancers to treat, with poor prognoses and limited effective options. Advancements that can improve survival or provide better administration modes, especially for pediatric patients, are significant.

The EMA’s positive opinion for Kizfizo broadens treatment options, especially introducing an oral suspension formulation better suited for young children. Orphan designation underscores the unmet medical need this medicine targets.

However, the benefits must be weighed carefully against side effects and the reality of limited overall survival gains typical in this disease area. Transparent communication about expected outcomes and side effects is essential for informed patient and clinician decision-making.

What to Verify Next

  • Review full clinical trial data supporting the CHMP opinion to assess detailed efficacy metrics, safety profiles, and trial populations.
  • Monitor post-marketing studies and real-world evidence to understand long-term benefits, side effects, and quality of life impacts.
  • Compare Kizfizo’s efficacy and tolerability with other treatment options, including newer therapies in development for glioma.
  • Verify the sustainability of the orphan designation status over time as new data emerge.
  • Consult the Summary of Product Characteristics (SmPC) once published for official clinical usage guidance and contraindications.
  • Explore patient and clinician experiences with the new oral suspension formulation, considering adherence and administration ease, especially in very young children.

Readers are encouraged to consult the European Medicines Agency’s official report and updates for comprehensive, verified information on Kizfizo and its regulatory status.

Source & verification

Primary source: New medicines and opinions: human · October 16, 2026

Read the original source

FreedomWitness links to the original source so readers can inspect the underlying material and judge the context for themselves.

Continue reading

Burkina Faso Targets Critics in Exile

Accountability in Burkina Faso: Evidence Dossier on Judicial Repression of Critics Abroad What is established Since a military coup in September 2022, the ruling…